|
RPS9 expression based on
|
Statistics: Unpaired two sample T-test was employed to evaluate levels of significance in expression level between any two sample groups
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.95488999999993E-05 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.170280E-04 |
| Normal-vs-Stage2 |
4.973400E-01 |
| Normal-vs-Stage3 |
3.99750000001919E-06 |
| Normal-vs-Stage4 |
1.104630E-03 |
| Stage1-vs-Stage2 |
1.874050E-01 |
| Stage1-vs-Stage3 |
5.595900E-02 |
| Stage1-vs-Stage4 |
6.611800E-01 |
| Stage2-vs-Stage3 |
1.680000E-02 |
| Stage2-vs-Stage4 |
1.459220E-01 |
| Stage3-vs-Stage4 |
2.544000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.80711999999694E-05 |
| Normal-vs-AfricanAmerican |
7.223900E-03 |
| Normal-vs-Asian |
2.641300E-03 |
| Caucasian-vs-AfricanAmerican |
3.890800E-01 |
| Caucasian-vs-Asian |
7.290800E-01 |
| AfricanAmerican-vs-Asian |
6.107400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.029500E-04 |
| Normal-vs-Female |
3.8230000000028E-05 |
| Male-vs-Female |
9.540000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.93487999999853E-05 |
| Normal-vs-Age(41-60Yrs) |
1.222450E-04 |
| Normal-vs-Age(61-80Yrs) |
2.679800E-02 |
| Normal-vs-Age(81-100Yrs) |
1.418010E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.850200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.058200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.775800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.366400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.093000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.968400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.144800E-01 |
| Classical-VS-Follicular |
7.18789999964997E-07 |
| Classical-VS-Other |
6.877200E-01 |
| Classical-VS-Normal |
5.5102999996226E-07 |
| Tall-VS-Follicular |
1.765230E-04 |
| Tall-VS-Other |
8.359000E-01 |
| Tall-VS-Normal |
7.607200E-04 |
| Follicular-VS-Other |
4.902000E-02 |
| Follicular-VS-Normal |
7.950400E-01 |
| Other-VS-Normal |
1.042430E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.006100E-04 |
| Normal-vs-N1 |
1.919090E-03 |
| N0-vs-N1 |
7.023000E-01 |
|
|
